Indivior Must Disband Suboxone Sales Force, Implement Executive Pay Recoupment Program
Executive Summary
$600m settlement with DOJ over Suboxone marketing includes corporate integrity agreement and exclusion of subsidiary from government health programs. Indivior also agrees to pay $10m to FTC and be enjoined from future antitrust violations.
You may also be interested in...
Indivior Inks Pact With Aelis For Cannabis Use Disorder Therapy
A market leader in opioid addiction, Indivior is expanding into the cannabis abuse space which is increasing exponentially due to widespread legalization of recreational use for the drug.
FTC Commissioner Changes Could Impact Pharma Mergers, Scrutiny Of Biosimilars Uptake
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.
Novartis To Make Its Medical Education Programs Virtual Under DOJ Settlement
Two settlements totaling $729m resolve kickback claims related to speaker programs and copay charities; Novartis will limit payments to healthcare professionals for providing medical education under a new corporate integrity agreement.